As anti-inflammatory space heats up, Pfizer spins JAK, TYK2 drugs into new startup
Having bet heavily on JAK inhibitors — putting together a portfolio anchored by Xeljanz and now Cibinqo — Pfizer is getting some help to develop its next such candidate.
But we don’t know who the partner is just yet.
In prepared remarks during Pfizer’s Q3 earnings call, CEO Albert Bourla revealed to investors that the company has exclusively licensed brepocitinib, a Phase II dual JAK/TYK2 inhibitor, to “a new company formed in collaboration with a partner that has a proven track record in late-stage inflammation and immunology drug development.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.